Phase 1 Study of Autologous anti-EGFRvIII synNotch Receptor Induced anti-EphA2/IL-13Rα2 CAR (E-SYNC) T Cells in Adult Participants with EGFRvIII+ Glioblastoma

The overall objective of this study is to determine the safety and feasibility of one infusion of E-SYNC T cells for the treatment of EGFRvIII+ glioblastoma. 

Sponsor

Hideho Okada, MD, PhD (UCSF)

Status of enrollment

Accepting new patients

Ages Eligible for Study

For people ages 18 years and up

Disease indication

Glioblastoma

Principal Investigator

Jennifer Clarke, MD, MPH

Contact

Jennifer Clarke, MD, MPH

Jennifer. [email protected]

 

Additional study eligibility details can be found at UCSF Clinical Trials.